anti-hbv

Cetylpyridinium Chloride (Hexadecylpyridinium Chloride) is a cationic quaternary ammonium compound used as oropharyngeal antiseptic.

Catalpol (Catalpinoside) is an iridoid glycoside with neuroprotective, anti-inflammatory, and anti-hepatitis virus effects.

Metacavir (PNA) is a novel nucleoside reverse transcriptase inhibitor, a deoxyguanosine analog, with anti-hepatitis B virus (HBV) activity and mitochondrial toxicity, which can be used to study HBV infection.

DDG-39 (1-(2,3-dideoxy-2-fluoropentofuranosyl)cytosine) possesses antiviral activity with potent and selective anti-HIV-1 and HBV activity in cell culture. The average antiviral IC50 is 0.61 μM.

Burfiralimab (hzVSF-v13) is a monoclonal immunoglobulin (IgG4) targeted against waveform proteins, exhibiting anti-HBV properties and potential applications in rheumatoid arthritis research.

Isothiafludine (NZ-4) is an orally active anti-HBV compound that acts by blocking the encapsulation of pre-genomic RNA (pgRNA) and interfering with nucleosome capsid assembly, and is used in the study of HBV infections.

Helioxanthin derivative 5-4-2 （Helioxanthin 5-4-2） is an analogue of helioxanthin that shows anti-HBV activity in vitro and can be used to study HBV.

Tenofovir amibufenamide (HS-10234) is a Tenofovir prodrug, an antiviral compound with oral activity. Tenofovir amibufenamide inhibits hepatitis B virus (HBV) and can be used in chronic hepatitis B (CHB) studies.

Punicalagin is a major ellagitannin found in pomegranates that is reported to produce antioxidant, anti-inflammatory, and anticancer effects. It has been shown to prevent high-fat diet-induced obesity-associated accumulation of cardiac triglyceride and ch

1, 2, 3, 4, 6-Pentagalloylglucose (Penta-O-galloyl-β-D-glucose) and gallic acid from Pistacia lentiscus have antimutagenic and antioxidant activities. 2. 1, 2, 3, 4, 6-Penta-O-galloyl-beta-D-glucose (PGG) possesses potent anti-proliferative and anti-invasive effects, it also has inhibition of inducible nitric oxide synthase and cyclooxygenase-2 activity. 3. PGG may serve as a model for the development of new types of anti-diabetic and anti-metabolic syndrome therapeutics. 4. 1, 2, 3, 4, 6-Penta- O -galloyl-β- d -glucose has vasodilatory and anti-inflammatory effects, it dilates vascular smooth muscle and suppresses the vascular inflammatory process via endothelium-dependent nitric oxide (NO)/cGMP signaling. 5. 1, 2, 3, 4, 6-Penta-O-galloyl-beta-D-glucose can decrease the level of extracellular hepatitis B virus (HBV) (IC5, 1. microg/ml) in a dose-dependent manner, it also can reduce the HBsAg level by 25% at a concentration of 4 microg/ml; the gallate structure of PGG may play a critical role in the inhibition of anti-HBV activity, suggests that PGG could be a candidate for developing an anti-HBV agent. 6. 1, 2, 3, 4, 6-Penta-O-galloyl-β-D-glucose has anti-parasitic activity, displays an EC5 value of 67 μM, at least 6.6-fold more effective than the standard drug benznidazole against trypomastigote forms of T. cruzi.

Punicalin exerts anti-inflammatory, antioxidative, and anti-hepatotoxic activities, it shows inhibitory activity on HIV-1 reverse transcriptase in a dose-dependent manner, with an IC50 of 0.11 microg ml (0.14 microM).

Bicyclol (SY801)(SY 801) is an anti-hepatitis drug. Oral administration of bicyclol normalizes the elevated serum transaminases (ALT, AST) by 50% in chronic viral hepatitis B and C, and also has a certain level of inhibiting HBV and HCV replication. In combination therapy of bicyclol with interferon alpha, lamivudine and adefovir dipivoxil in HBV or HCV, bicyclol may reduce YMDD mutant and side effects and increase the anti-viral efficacy.

NVR 3-778 is a first-in-class, orally bioavailable HBV CAM belonging to the SBA class, exhibiting anti-HBV activity.

Chamaechromone is a natural product isolated from the roots of Stellera chamaejasme L.. Chamaechromone has anti-HBV and insecticidal activity.

1. Swertianolin (Bellidifolin-8-O-Glucoside), mangiferin, rhodenthoside A-C, isoorientin, isovitexin, and amarogentin would serve as potential chemotaxonomic markers to differentiate Gentianaceae species. 2. Swertianolin and swertiamarin show significant hepatoprotective effect in the liver damage model induced by alpha-naphthylisot hiocyanate. 3. Swertianolin shows anti-acetylcholinesterase activity effects. 4. Swertianolin shows that it can scavenge superoxide and hydroxyl radicals with the studying method of the autoxidation of Pyrogallol and afenton.

OSS_128167 (SIRT6-IN-1) is a specific SIRT6 inhibitor, and for SIRT6(IC50=89 μM), SIRT1(IC50=1578 μM) and SIRT2(IC50=751 μM).

6-Chloro-2-fluoropurine is a heterocyclic building block.1,2It has been used in the synthesis of purine nucleosides that inhibit cyclin-dependent kinases (CDKs)in vitro.16-Chloro-2-fluoropurine has also been used in the synthesis of purine nucleosides that are active against HIV-1 and hepatitis B virus (HBV)in vitro.2 1.Wilson, S.C., Atrash, B., Barlow, C., et al.Design, synthesis and biological evaluation of 6-pyridylmethylaminopurines as CDK inhibitorsBioorg. Med. Chem.19(22)6949-6965(2011) 2.Lee, K., Choi, Y., Gullen, E., et al.Synthesis and anti-HIV and anti-HBV activities of 2'-fluoro-2',3'-unsaturated L-nucleosidesJ. Med. Chem.42(7)1320-1328(1999)

Dihydrodehydrodiconiferyl alcohol 9-O-α-L-rhamnopyranoside (Compound 1), a lignan with anti-HBV activity, selectively targets the HBV surface antigen (HBsAg) with an IC50 of 0.58 mM, while its activity against the HBV e antigen (HBeAg) is significantly lower, with an IC50 of >2.4 mM. This compound can be isolated from the plant star anise [1].

IR415 selectively interacts with Hepatitis B virus X protein (HBx, Kd = 2 nM) and blocks HBV-mediated RNAi suppression, reverses the inhibitory effect of HBx protein on the activity of the dicer endoribonuclease. IR415 is a potent anti-HBV agent and inhibits HBV replication by blocking the HBx activity.

Schisanwilsonin D, and schisantherin C show anti-HBV activity.

Junceellolide C, a potent anti-HBV agent, acts as a transcription inhibitor of cccDNA, effectively inhibiting HBV DNA replication and significantly reducing supernatant HBV RNA levels in HepAD38 cells, with EC50 values of 5.19 and 3.52 μM, respectively.

Herpetone exhibits protective effects on CCl(4)-induced hepatocyte injury, it shows anti-hepatitis B virus (HBV) activity.

Yhhu6669 is an anti-HBV agent that suppresses viral DNA and replication by promoting DNA-free capsid assembly, effectively reducing HBV DNA and HBcAg levels in AAV/HBV-infected mice and demonstrating favorable pharmacokinetic (PK) properties [1].

Lagociclovir valactate, a prodrug of Lagociclovir, is an orally active anti-HBV agent [1].

Dihydrodehydrodiconiferyl alcohol 9-O-β-D-xylopyranoside serves as an anti-hepatitis B virus (anti-HBV) agent, effectively inhibiting the secretion of HBV surface antigen (HBsAg) and HBV e antigen (HBeAg) in the Hep G2.2.15 cell line, with IC50 values of 1.67 mM for HBsAg and over 2.15 mM for HBeAg [1].

Vonafexor (EYP001) is a farnesoid X receptor (FXR, NR1H4) agonist, with anti-HBV effects

Neracorvir, a potent antiviral agent, exhibits anti-HBV activity.

HBV-IN-31, a potent inhibitor of covalently closed circular DNA (cccDNA), demonstrates significant anti-HBV activity by inhibiting cell growth and exhibiting an IC50 value of 0.13 µM for HBsAg.

Neochlorogenic acid methyl ester (5-O-Caffeoylquinic acid methyl ester), derived from Artemisia capillaris and black chokeberry [Aronia melanocarpa] fruits, exhibits weak anti-HBV activity, antioxidant properties, and quinone reductase activity with a CD of 6.7 μM.

Helioxanthin 8-1, an analogue of helioxanthin, exhibits significant in vitro anti-HBV/HCV/HSV-1/HIV activity with EC50 of >5/10/1.4/15 μM.

1. 4,5-Dicaffeoylquinic acid (Isochlorogenic acid C) has antiviral activity, including anti-HIV-1 integrase activity. 2. 4,5-Dicaffeoylquinic acid (Isochlorogenic acid C) shows anti-hepatotoxic activity.

Pedunculosumoside F, a homoflavonoid glucoside extracted from Ophioglossum pedunculosum, exhibits cytotoxicity against HepG2 22.15 cells, presenting a CC50 value of 56.7 μM, yet lacks anti-HBV activity. Conversely, its analogs inhibit HBsAg secretion in HBV-infected HepG2 2.2.15 cells [1].

Bentysrepinine, a novel anti-HBV agent, inhibits DNA-HBV and cccDNA activities for the treatment of hepatitis B virus (HBV)-infected hepatitis.

L-2'-Fd4C is an L-nucleoside analogue with both anti-human immunodeficiency virus (HIV) and anti-hepatitis B virus (HBV) activity [1].

HBV-IN-36 (also known as compound 42) is a hepatitis B virus (HBV) inhibitor with an IC50 of 2 μM, exhibiting anti-HBV activity characterized by an EC50 of 0.58 μM [1].

Compound HBV-IN-35 (Compound 88) serves as an HBV inhibitor and exhibits anti-HBV activity in both mouse and human hepatocytes with EC50 values of 100 nM and 400 nM, respectively [1].

HBV-IN-34 (compound 17i) is a potent inhibitor of HBsAg production, exhibiting strong in vitro anti-HBV efficacy with an EC50 of 0.018 μM for HBV DNA and 0.044 μM for HBsAg [1].

HBV-IN-25 is a novel chemical compound that acts as a potent HBV cccDNA reducer when administered orally. It exhibits significant anti-HBeAg potency and anti-HBV activity, with IC50 values of 0.58 μM and 1.15 μM, respectively. Moreover, HBV-IN-25 demonstrates favorable aqueous solubility (LYSA＞452 μg/mL) and no cellular toxicity, making it a promising candidate for further investigation and development [1].

HBV-IN-4, a derivative of phthalazinone, functions as a potent, orally active inhibitor of HBV DNA replication, exhibiting an IC50 value of 14 nM. It effectively induces the formation of genome-free capsids, demonstrating significant anti-HBV potency[1].

HBV-IN-32, a potent inhibitor of covalently closed circular DNA (cccDNA), exhibits significant anti-Hepatitis B Virus (HBV) activity by achieving an IC50 of 0.14 µM against HBsAg. Additionally, it impedes cell growth.

(+)-Sophoranol exhibits antiviral activity against the Coxsackie virus B3. It also shows potent anti-HBV activity with an inhibitory potency against HBsAg secretion and against HBeAg secretion.

Firzacorvir, a cyclic sulfamide compound, functions as an HBV core protein modulator and demonstrates potent anti-HBV activity, with an EC50 value of < 1 μΜ.

Z060228 is an potent anti-HBV inhibitor. The HBV DNA replication was effectively inhibited by Z060228 in the supernatants of the HepG2.2.15 cells. Z060228 exhibited effects on the self-assembly of Cp149. SEC data revealed that Z060228 altered the equilibr

L-Fd4A (compound 36) is an adenine derivative that has anti-human immunodeficiency virus (HIV) (EC 50 =1.5 μM) and anti- hepatitis B virus (HBV) ( EC 50 =1.7 μM) activity. L-Fd4A has low cytotoxicity [1].

Brain Derived Basic Fibroblast Growth Factor (1-24) (FGF basic 1-24), a synthetic peptide with anti-bacterial and anti-HBV properties, is utilized in infectious and immune disease research [1].

Exbivirumab is an anti-hepatitis B virus monoclonal antibody (anti-HBV mAb) that amplifies the antiviral effects of hepatitis B immunoglobulin (HBIG) [1].

Coclauril shows anti-Hepatitis B virus (HBV) activities, with EC50 values of 7.6 ± 0.5 ug/mL.

HBV-IN-23 (Compound 5k) is an inhibitor of HBV DNA replication with an IC50 of 0.58 μM, inhibiting both drug-sensitive and drug-resistant strains. It induces apoptosis in HepG2 cells and demonstrates anti-hepatocellular carcinoma (HCC) effects.

HBV-IN-12 is a potent inhibitor of hepatitis B surface antigen (HBsAg) with an EC50 range of 0.001 μM to 0.05 μM and demonstrates anti-HBV DNA activity with an EC50 range of 0.001 μM to 0.02 μM.